

Important safety information for patients treated with:

XIMLUCI[®] ▼ (ranibizumab)

with visual impairment due to
choroidal neovascularisation (CNV)
secondary to pathological myopia

This booklet was created to help you better understand
XIMLUCI[®] when used for the treatment of the following condition:
Choroidal neovascularisation (CNV)

Reporting of side effects. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

You can help by reporting any side effects you may experience. You can report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. Side effects should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.

Summary of important safety information

Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with XIMLUCI®:

- Pain
- Light sensitivity/tearing
- Swollen lids or other swelling
- Light flashes
- Seeing flies, black spots or coloured halos
- Drying of the surface of your eye
- Increasing redness
- Blurred, distorted or sudden loss of vision

What is XIMLUCI®?

In diseases such as CNV, abnormal blood vessels grow in the eye, which can leak and cause vision loss.

XIMLUCI® specifically recognises and blocks the action of new blood vessel growth in the eye, and so in turn can help to stop leakage and vision loss.

Why have I been prescribed XIMLUCI®?

CNV

- CNV is a condition that affects the macula, a part of the retina at the back of the eye
- The macula is the area that lets you see sharply in the centre of your vision
- CNV is the growth of new, weak blood vessels under the macula, which can leak fluid and blood into the retina, affecting your central vision
- CNV is observed in age-related macular degeneration (AMD); it may also be associated with other diseases. These include CNV due to pathologic myopia (PM), angioid streaks or central serous chorioretinopathy (CSC), and inflammatory CNV

How is XIMLUCCI® treatment given?

XIMLUCCI® is given by your ophthalmologist (eye doctor) as an injection into the eye.

It is normal to worry about such injections, but usually the injection is virtually painless.

What will happen at my appointment?

On the day of your treatment, care will be taken to make sure you are relaxed and comfortable

Before receiving XIMLUCCI®, it is important to tell your doctor if:

- > You have had a stroke or experienced transient signs of stroke (weakness or paralysis of limbs or face, difficulty speaking or understanding)
- > You are taking or have recently taken any other medicines, including medicines obtained without prescription
- > You have an eye infection
- > You have any pain or redness in your eye
- > You think you may be allergic to XIMLUCCI® or to Betadine® (iodine)

Keeping your doctor informed will help them to decide whether XIMLUCCI® is the most appropriate treatment for you

A doctor or nurse will:

- > Cover your face and the area around the eye with a special drape
- > Clean your eye and the skin around it
- > Hold your eye open so you do not blink
- > Numb your eye with an anesthetic to prevent pain

The doctor will then give the injection into the white part of your eye. You may feel a little pressure with the injection.

After treatment

What will happen after I receive my XIMLUCI[®] injection?

Your doctor will perform eye tests, such as measuring the pressure in your eye, to make sure the treatment went well.

The white area of the eye, where the injection is given, will likely be red.

- > This redness is normal and it will go away in a few days

You may see a few spots or 'floaters' in your vision.

- > These spots are normal and should go away in a few days

Contact your doctor if either of these symptoms do not go away or get worse.

Your pupils will be dilated for the injection, and this can make it difficult for you to see for a few hours after the treatment.

- > You should not drive until your vision has returned to normal

It is important to monitor any changes in the condition of your eye and your overall well-being in the week following your injection.

Rarely, injections in the eye can cause infection.

Contact your doctor as soon as possible if you have any of the following signs and symptoms in your eye:

- Pain
- Light sensitivity/tearing
- Swollen lids or other swelling
- Increasing redness
- Blurred, distorted or sudden loss of vision
- Light flashes
- Seeing flies, black spots or coloured halos
- Drying of the surface of your eye

If you notice any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

By reporting side effects you can help provide more information on the safety of this medicine.

You can report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Side effects should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.

How long will I need to continue XIMLUCI® treatment?

Every patient is different. It is likely that you will need additional XIMLUCI® injections, but this will depend on how you respond to treatment and how your vision changes.

If you are considering stopping treatment with XIMLUCI®, ask your doctor for advice first.

For any further questions on the use of this product, please ask your doctor.

Follow all your doctor's advice carefully. They may differ from the general information in this booklet.

Your doctor will decide how often they wish to see you to monitor your condition and determine if you need additional injections.

Always go to every appointment that your doctor arranges for you.

If you miss an appointment for XIMLUCI® treatment, contact your doctor as soon as possible.

Keep this booklet; you may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

If you experience any signs or symptoms that you consider to be associated with the use of XIMLUCI®, but are not listed in this booklet, please tell your doctor.

This booklet is provided for your education and complements the Patient Information Leaflet.